Enliven Therapeutics Q4 net loss widens on higher expenses

Enliven Therapeutics

03/03/2026 21:29

Overview

Biopharmaceutical company reported higher Q4 net loss of $29.7 mln, with strong cash position

Outlook

Enliven maintains a strong cash position, projected to support operations into 2029

Result Drivers

R&D expenses were $21.2 million for the fourth quarter of 2025, compared to $20.7 million for the fourth quarter of 2024

Company press release: ID:nPndQV86a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$29.67 mln
Q4 Basic EPS
-$0.48
Q4 Income From Operations
-$34.29 mln
Q4 Operating Expenses
$34.29 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Enliven Therapeutics Inc is $39.00, about 32.2% above its March 2 closing price of $29.50

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)